Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares to Fund Pipeline Advancement and Corporate Growth

Eupraxia Pharmaceuticals plans to raise funds through a public offering of common shares, with joint book-running managers Cantor and LifeSci Capital, and co-manager Bloom Burton. The net proceeds will be used to advance the company's product pipeline, complete ongoing studies and clinical trials, and support general corporate purposes. The offering is expected to be priced in the context of the market, with the final terms to be determined at the time of pricing.

Eupraxia Pharmaceuticals Inc. (EPRX) has announced a proposed public offering of common shares, aiming to raise funds to advance its product pipeline and support ongoing clinical trials. The offering will be managed by Cantor and LifeSci Capital as joint book-running managers, with Bloom Burton acting as co-manager. The proceeds will primarily fund the company's product pipeline development, including ongoing clinical trials, regulatory submissions, and commercial preparation. Additionally, the funds will be used for research and development (R&D) for pipeline candidates, business development, and general corporate purposes.

The company has filed a preliminary prospectus supplement to its base shelf prospectus for the offering, which includes a 30-day option for underwriters to purchase up to an additional 15% of shares. The final terms and size of the offering will be determined at pricing, subject to customary conditions including TSX and Nasdaq listing approvals.

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company specializing in extended-release therapies through its proprietary DiffuSphere™ technology. The company's key clinical programs include EP-104GI, which is in Phase 1b/2a for eosinophilic esophagitis (EoE) treatment, and EP-104IAR, which recently completed a successful Phase 2b trial for knee osteoarthritis pain. The company's recent positive clinical results from the RESOLVE trial have shown promising outcomes with sustained treatment effects after 12 months of therapy.

The company's cash position stands at $19.8 million as of June 30, 2025, which is expected to fund operations into Q3 2026. The company's financial results for Q2 2025 showed a net loss of $8.7 million compared to $6.1 million in Q2 2024. Eupraxia Pharmaceuticals is also actively participating in several upcoming investor conferences in August and September 2025 to present its latest developments and clinical data.

The company's recent clinical trial results and financial updates indicate a strong commitment to advancing its product pipeline and addressing unmet medical needs through innovative drug delivery science.